Table 1.
Characteristics of the 25 patients that were treated based on their MoMP. Listed are patients’ GMI, receptor status of the metastatic lesion, metastatic site, targets used for treatment selection, and MoMP‐based selected treatment.
| Subject ID | GMI | Previous therapies | Receptor Status* | Target lesion | MoMP Targets | MoMP‐based Treatment | |
|---|---|---|---|---|---|---|---|
| 02‐027 |
0.3 0.4 |
8 | ER+/PR‐/HER2‐ | Omentum | AR; ER; TOPO1 | Megestrol Acetate (1st line); Irinotecan (2nd line) | |
| 02‐012 |
0.4 1.3 |
7 | ER+/PR+/HER2‐ | Liver | AR; ER; TOPO1; TS | Capecitabine; Irinotecan (1st line); Megestrol Acetate (2nd line) | |
| 02‐037 | 0.5 | 4 | ER+/PR+/HER2‐ | Liver | TOPO1 | Irinotecan | |
| 02‐043 | 0.5 | 7 | ER+/PR‐/HER2‐ | Liver | No biomarker(s) | Eribulin | |
| 02‐008 | 0.5 | 7 | ER+/PR+/HER2‐ | Chest wall/Skin | ER; p‐p70S6K | Everolimus; Exemestane | |
| 02‐006 | 0.6 | 1 | ER+/PR‐/HER2‐ | Lymph node | p‐AKT; p‐HER2; p‐HER3; p‐ERK; TS | Capecitabine; Lapatinib | |
| 02‐007** |
0.7 1.0 1.9 |
3 | ER+/PR‐/HER2‐ | Chest wall/Skin | ER; p‐HER2; p‐ERK; TOPO1 | Irinotecan (1st line); Lapatinib; Letrozole (2nd line); Eribulin (3rd line) | |
| 02‐021 | 0.8 | 2 | ER+/PR‐/HER2‐ | Omentum | ER; p‐p70S6K | Everolimus; Exemestane | |
| 02‐032 | 0.8 | 4 | ER‐/PR‐/HER2‐ | Chest wall/Skin | No biomarker(s) | Eribulin | |
| 02‐018 | 0.9 | 3 | ER+/PR‐/HER2‐ | Liver | TS, TYMP*** | Capecitabine | |
| 02‐041 | 1.2 | 1 | ER‐/PR‐/HER2‐ | Chest wall/Skin | TOPO1 | Irinotecan | |
| 02‐020 | 1.3 | 5 | ER+/PR‐/HER2‐ | Liver | ER; p‐p70S6K | Everolimus; Exemestane | |
| 02‐023**** |
1.3 1.7 |
1 | ER‐/PR‐/HER2‐ | Liver & Lymph node | EZH2****; Survivin****; TOPO1; TS; TUBB3**** | Capecitabine; Irinotecan (1st line); Paclitaxel (2nd line) | |
| 02‐039 | 1.4 | 9 | ER‐/PR‐/HER2+ | Lung | TOPO1; HER2; p‐HER2; p‐ERK | Irinotecan; Trastuzumab | |
| 02‐014 | 1.4 | 7 | ER+/PR‐/HER2‐ | Lung | TOPO1 | Irinotecan | |
| 02‐025 | 1.8 | 1 | ER+/PR‐/HER2‐ | Lymph node | TS | Capecitabine | |
| 02‐009 |
2.2 1.1 |
18 | ER+/PR+/HER2‐ | Abdominal mass | AR; ER; TS | Megestrol Acetate (1st line); Capecitabine; Vinorelbine (2nd line) | |
| 02‐003 | 2.4 | 1 | ER+/PR‐/HER2‐ | Liver | SPARC | Nab‐paclitaxel | |
| 02‐017 | 2.8 | 1 | ER+/PR‐/HER2‐ | Liver | TS; p‐EGFR; p‐HER2; p‐HER3; p‐ERK | Capecitabine; Lapatinib | |
| 02‐029***** | 3.8 | 2 | ER‐/PR‐/HER2‐ | Chest wall/Skin | TOPO1 | Irinotecan | |
| 02‐036 | 4.2 | 1 | ER+/PR‐/HER2‐ | Liver | TOPO1; TS | Capecitabine; Irinotecan | |
| 02‐010 | 6.1 | 5 | ER+/PR+/HER2‐ | Liver | TOPO1 | Irinotecan | |
| 02‐019 | 7.2 | 9 | ER‐/PR‐/HER2+ | Chest wall/Skin | p‐EGFR; p‐HER2; p‐HER3; p‐ERK; HER2; HER3. | Docetaxel; Pertuzumab; Trastuzumab | |
| 02‐011 | 8.5 | 3 | ER‐/PR‐/HER2‐ | Liver | TOPO1; TS | Capecitabine; Irinotecan | |
| 02‐028 | 15.9 | 1 | ER+/PR‐/HER2‐ | Chest wall/Skin | TS | Capecitabine | |
*
HER2 status was determined by CISH and ER and PR status by IHC.
**
Metastatic lesion from a male breast tumor.
***
Thymidine Phosphorylase.
****
A second biopsy was collected from the same patient after recurrence.
*****
HER2 status attributed based on whole exome sequencing analysis.